Journal
JOURNAL OF DERMATOLOGY
Volume 47, Issue 12, Pages 1436-1438Publisher
WILEY
DOI: 10.1111/1346-8138.15577
Keywords
enfortumab vedotin; full-thickness epidermal necrosis; molecular-targeted therapy; severe drug eruption; tumor-infiltrating leukocytes
Categories
Ask authors/readers for more resources
Enfortumab vedotin (EV) is a novel, fully humanized monoclonal antibody-drug conjugate composed of an anti-Nectin-4 antibody joined to monomethyl auristatin E. In this report, we described a case of a severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing in patients with metastatic urothelial cancer treated with EV. Because phase II and phase III clinical studies are ongoing, in the future, substantial amounts of EV are expected to be used for the treatment of metastatic urothelial cancer. Therefore, understanding the mechanisms of drug eruption caused by EV is important for oncologists as well as dermatologists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available